Abstract Library

#4540 Retrospective analysis of somatostatin receptors expression in cohort of thoracic neuroendocrine neoplasms with immunohistochemistry method or PET/CT Ga68 DOTA-TATE

Introduction: Somatostatin receptors (SSTRs) expression in cohort of thoracic neuroendocrine neoplasms (NENs) is still not fully described. We attempted to evaluate the SSTR expression by IHC and PET/CT with Ga68 DOTA-TATE, as well as the sensitivity of both methods.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Vorobeva M, Zhulikov Y, Markovich A, Gorbunova V,

Keywords: NEN, thoracic, SSTR, IHC, DOTATATE, lung, thymus, mediastinum, LCNC, NET,

#3886 Large cell neuroendocrine carcinoma subtyping based on NEUROD1, ASCL1, POU2F3 and YAP1 expression

Introduction: Large cell neuroendocrine carcinoma (LCNEC) accounts for 1-3% of all types of lung cancer and is, similar to small-cell lung cancer (SCLC), a high-grade tumor with poor prognosis. pRb can also be used to subclassify LCNEC into SCLC-like and NSCLC-like. SCLC can be classified in 4 transcriptomic subtypes (NEUROD1high, ASCL1high, POU2F3high, YAP1high), which may have therapeutic implications. It is unclear whether these subtypes are also found in LCNEC and if they correlate with pRb expression.

Conference:

Presenting Author: Heijboer F

Authors: Rijnsburger N, Heijboer F, Derks J, Hermans B, Hillen L,

Keywords: LCNEC, pulmonary, immunohistochemistry, pathology, pRb, transcription factors,

#3835 Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine cancer

Introduction: 28% of low-grade neuroendocrine tumors (NETs) present at advanced stages and are unresponsive to therapy, pointing to a gap in our understanding of how these tumors arise and progress.

Conference:

Presenting Author: Dayton T

Authors: Dayton T, Alcala N, Moonen L, den Hartigh L, Mangiante L,

Keywords: Organoids, LCNEC, NET, pulmonary carcinoid, EGF,

#3702 The role of the somatostatin analogues in large cell neuroendocrine carcinomas treatment

Introduction: Large cell neuroendocrine carcinoma (LCNEC) is still a poorly studied disease with low somatostatin receptors expression, so we have scant data on the effectiveness of the somatostatin analogues (SSA) in this disease.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Artamonova E, Delektorskaya V, Yemelyanova G, Markovich A,

Keywords: NEC, SSTR, somatostatin analogues, large cell carcinoma, SSA, LCNEC, somatostatin receptor,

#3559 Novel patient-derived tumor organoid models reveal growth-factor dependencies in neuroendocrine tumors and serve as a platform for neuroendocrine cancer research

Introduction: Neuroendocrine neoplasms (NENs) comprise neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). While NETs are well-differentiated and progress slowly, NECs are poorly differentiated and have a poor prognosis. Irrespective of subtype, treatment options for patients with unresectable, relapsed, or metastasized NENs are limited, in part due to lack of accurate models to study these diseases.

Conference:

Presenting Author: Dayton T

Authors: Dayton T, Alcala N, Moonen L, van den Berg J, Buikhuisen W,

Keywords: patient derived tumor organoids, pulmonary NET, LCNEC, growth-factor dependency,